A pioneering life science and drug development company specialising in non-invasive drug development
Nottingham University spinout, Exonate, is developing a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DME), by using mRNA targeted therapies. It’s Exonate’s mission to develop a unique, low side-effect treatment that can significantly improve patients’ quality of life.
Our Cambridge team was hired to elevate Exonate’s profile within the market, and change the way that the company’s science and strategy are communicated. The new website showcases Exonate's pioneering technology and presents their investors and key members of the advisory board, helping to build trust in the company and drive online business development and partnership enquiries.